


# Complement inhibition in neuromyelitis optica spectrum disorder and refractory generalized myasthenia gravis\*

**From trials to real-world  
clinical practice**

**12:15–13:15 CEST  
Sunday 20 June 2021**



**Registered delegates  
will be able to join the symposium via  
the EAN platform at [www.ean.org/congress2021](http://www.ean.org/congress2021)**

## **PROGRAM**

- 12:15–12:20 Welcome and introduction**  
Professor Sven Meuth (Germany)
- 12:20–12:30 Scientific innovation connected through complement**  
Professor Sven Meuth (Germany)
- 12:30–12:45 A complementary approach to patient care in AQP4+ neuromyelitis optica spectrum disorder**  
Professor Orhan Aktas (Germany)
- 12:45–13:00 Applying the science of complement inhibition in refractory AChR+ generalized myasthenia gravis**  
Professor Amelia Evoli (Italy)
- 13:00–13:15 Panel discussion, audience questions and close**  
All

\*This symposium will focus on data relating to neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease and refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive.

This symposium is intended for healthcare professionals only.

Educational meeting organized and funded by Alexion Pharmaceuticals for healthcare professionals only. Please note, Alexion products will be presented as part of this meeting.

Registration conditions differ internationally, and prescribing information may vary depending on approval in each country.